Fedor Moiseenko
YOU?
Author Swipe
View article: Venous thromboembolic complications in patients with cancer: a review of the literature
Venous thromboembolic complications in patients with cancer: a review of the literature Open
Tumour-associated thrombosis, deep vein thrombosis of the lower leg, pulmonary embolism
View article: Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer
Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer Open
The efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) varies widely across patients. Growing evidence indicates that the gut microbiome, through its interaction with the tumor microenvironment, may influ…
View article: Prognostic model integrating histology, systemic inflammation, and recurrence status predicts immunotherapy response in advanced non-small-cell lung cancer patients
Prognostic model integrating histology, systemic inflammation, and recurrence status predicts immunotherapy response in advanced non-small-cell lung cancer patients Open
View article: Efficacy of hormone therapy as first-line treatment in patients with er-low her2-metastatic breast cancer: real world data
Efficacy of hormone therapy as first-line treatment in patients with er-low her2-metastatic breast cancer: real world data Open
ER-low, metastatic breast cancer, endocrine therapy, iCDK4/6, chemotherapy
View article: The effectiveness of neoadjuvant hormone therapy in comparison with neoadjuvant polychemotherahy in hr+ her2- invasive lobular breast cancer (single-center retrospective study)
The effectiveness of neoadjuvant hormone therapy in comparison with neoadjuvant polychemotherahy in hr+ her2- invasive lobular breast cancer (single-center retrospective study) Open
neoadjuvant hormonal therapy, neoadjuvant polychemotherapy, lobular breast cancer, breast-conserving surgery.
View article: Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations
Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations Open
Background/Objectives: Checkpoint inhibitors (ICIs) are key therapies for NSCLC, but current selection criteria, such as excluding mutation carriers and assessing PD-L1, lack sensitivity. As a result, many patients receive costly treatment…
View article: Ten Years of Experience in the Department of Centralized Drug Dilution at St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov
Ten Years of Experience in the Department of Centralized Drug Dilution at St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov Open
Введение. На фоне возрастающего объема используемой специфической лекарственной терапии по всей стране создаются рекомендации и инструкции по использованию противоопухолевых препаратов, а также внедряются кабинеты и отделения централизован…
View article: Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer
Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer Open
Equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) was demonstrated in a phase 3 study of patients with metastatic or recurrent non-squamous NSCLC. Long-term findings …
View article: RADIOTHERAPY IN PATIENTS WITH INOPERABLE NSCLC DURING THERAPY WITH CHECKPOINT INHIBITORS
RADIOTHERAPY IN PATIENTS WITH INOPERABLE NSCLC DURING THERAPY WITH CHECKPOINT INHIBITORS Open
NSCLC, immunotherapy, oligometastasis, radiotherapy.
View article: ROLE OF RADIOTHERAPY IN TREATMENT OF NON-OPERABLE EGFR-MUTATED NSCLC
ROLE OF RADIOTHERAPY IN TREATMENT OF NON-OPERABLE EGFR-MUTATED NSCLC Open
Non small cell lung cancer, radiotherapy, EGFR mutation.
View article: Злокачественные опухоли печени и желчевыводящей системы
Злокачественные опухоли печени и желчевыводящей системы Open
.
View article: Нейроэндокринные неоплазии лёгких и тимуса
Нейроэндокринные неоплазии лёгких и тимуса Open
В данном разделе указаны критерии оценки клинической значимости применения дорогостоящей противоопухолевой лекарственной терапии в соответствии со шкалой, разработанной экспертной группой (стр. 6). В тексте они обозначены, как магнитуда кл…
View article: Немелкоклеточный рак легкого
Немелкоклеточный рак легкого Open
.
View article: Long-term outcomes of durvalumab after chemoradiotherapy in locally advanced non-small cell lung cancer in Russia
Long-term outcomes of durvalumab after chemoradiotherapy in locally advanced non-small cell lung cancer in Russia Open
Introduction. The results of the PACIFIC trial have changed the standards of care for the patients with unresectable stage III nonsmall cell lung cancer (NSCLC). However, many patients in our clinical practice do not meet the inclusion cri…
View article: Clinical prognostic factors for the effectiveness of immunotherapy in patients with unresectable NSCLC
Clinical prognostic factors for the effectiveness of immunotherapy in patients with unresectable NSCLC Open
: based on the univariate Cox regression model, six clinical characteristics showed a statistically significant effect on overall survival: sex, lymph node involvement, use of chemotherapy in the first line of treatment, low neutrophil cou…
View article: Extended and two-staged liver resections in patients with colorectal liver metastases
Extended and two-staged liver resections in patients with colorectal liver metastases Open
The questions of liver resection volume in patients with colorectal liver metastases are controversial and solved by specialists differently, taking into account the characteristics of the tumor lesion, the surgeon’s own experience and the…
View article: Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial Open
PURPOSE Telisotuzumab vedotin (Teliso-V) is a c-Met–directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial (ClinicalTrials.gov identifier: NCT03539536 ) aimed to identify the optima…
View article: Possibilities of Liquid Biopsy in Determining the Mechanisms of Resistance to Osimertinib
Possibilities of Liquid Biopsy in Determining the Mechanisms of Resistance to Osimertinib Open
Цель. Выявление механизмов резистентности к осимертинибу в циркулирующей опухолевой ДНК (цоДНК). Материалы и методы. В рамках исследования Trust (многоцентровое неинтервенционное ретро- и проспективное исследование безопасности и эффективн…
View article: Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience
Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience Open
Genomic profiling, or molecular profiling of the tumor, is becoming a key component of therapeutic decision making in clinical oncology, and is typically carried out via next generation sequencing. However, the interpretation of the result…
View article: Long-term outcomes of neoadjuvant endocrine therapy versus chemotherapy in luminal HER2-breast cancer
Long-term outcomes of neoadjuvant endocrine therapy versus chemotherapy in luminal HER2-breast cancer Open
Introduction. Neoadjuvant endocrine therapy (NET) is an effective treatment modality that can downsize breast tumors in a cohort of postmenopausal women with HR-positive HER2-negative breast cancer. A lack of data regarding efficacy of NET…
View article: Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia Open
Background. Prior to the introduction of new agents — immune checkpoint inhibitors — for inoperable and/or metastatic melanoma (IMM), chemotherapy outcomes were generally poor. The median (Me) overall survival (OS) in IMM was no more than …
View article: Analysis of the work of the central chemotherapy drugs breeding department in the State Medical Institution «St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov» 2014–2022
Analysis of the work of the central chemotherapy drugs breeding department in the State Medical Institution «St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov» 2014–2022 Open
Aim of the study. Analysis of the efficiency of the central chemotherapy drugs breeding department in the medical institution of oncological profile using the example of «St. Petersburg Clinical Scientific and Practical Center of Specializ…
View article: Efficacy of neoadjuvant endocrine therapy in HR-positive/HER2-negative breast cancer: A review
Efficacy of neoadjuvant endocrine therapy in HR-positive/HER2-negative breast cancer: A review Open
IMPORTANCE. Neoadjuvant endocrine therapy (NET), despite demonstrating comparable data to neoadjuvant chemotherapy (NACT) in regard to ORR and being a less toxic alternative, is still used in clinical practice mainly for elderly patients o…
View article: Злокачественные опухоли печени и желчевыводящей системы
Злокачественные опухоли печени и желчевыводящей системы Open
.
View article: Нейроэндокринные неоплазии лёгких и тимуса
Нейроэндокринные неоплазии лёгких и тимуса Open
.
View article: Немелкоклеточный рак легкого
Немелкоклеточный рак легкого Open
.
View article: Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study Open
Background. In an era of breakthroughs in cancer immunotherapy, CheckMate 067 studies declared the combination of PD-1 and CTLA-4 inhibitors a new standard of care for patients with metastatic melanoma (MM). A significant limitation of the…
View article: Pathogenetic Mechanisms of the Relationship between Chronic Obstructive Pulmonary Disease and Lung Cancer
Pathogenetic Mechanisms of the Relationship between Chronic Obstructive Pulmonary Disease and Lung Cancer Open
Рак легкого и хроническая обструктивная болезнь легких являются самыми распространенными причинами смерти пациентов во всем мире. В основе этиологии этих болезней лежат изменения альвеолоцитов и других клеток, выстилающих поверхность легоч…
View article: Cardiovascular Monitoring of Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: Preliminary Results from a Prospective Observational Study
Cardiovascular Monitoring of Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: Preliminary Results from a Prospective Observational Study Open
Background: the whole spectrum of Immune Checkpoint Inhibitors (ICI) associated cardiovascular immune related adverse events is not fully understood. Only last years it became clear that ICI may cause not only inflammatory cardiovascular d…
View article: 52P The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
52P The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients Open